Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new imaging tracer light up ovarian cancer cells?

NCT ID NCT07790939

Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests a new PET/CT tracer called 89Zr-DFO-Mirvetuximab, which targets a protein (FRα) found on many ovarian cancer cells. Researchers will give the tracer to 20 people with advanced or recurrent ovarian cancer and take scans at several time points. They will compare these images with standard FDG PET/CT scans to see if the new tracer better identifies and outlines cancer lesions. The goal is to improve detection and help guide treatment decisions for ovarian cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
89Zr-DFO-Mirvetuximab, a radioactive tracer for PET/CT imaging that targets a protein called FRα found on many ovarian cancer cells
What this could lead to
If it works, this imaging method could help doctors see ovarian cancer more clearly and choose the right patients for FRα-targeted therapies, improving treatment outcomes.
What could go wrong
This is an early, small study with 20 participants. The tracer may not reliably show all lesions, and its safety and effectiveness need further testing before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with newly diagnosed stage IV ovarian cancer or first-recurrent ovarian cancer, aged \>18 years. 2. No clinically significant abnormalities in complete blood count, liver function, or renal function. 3. Estimated life expectancy ≥6 months. 4. At least one measurable target lesion per RECIST version 1.1. 5. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days prior to the start of the study procedures; patients with reproductive potential must agree to use effective contraception to avoid pregnancy during the study and within 3 months after the last imaging examination. 6. Female patients must adopt effective contraceptive measures throughout the study period and for 6 months after study completion. 7. Patients must fully understand and voluntarily participate in the trial, and provide written informed consent. Exclusion Criteria: 1. Severe hepatic or renal dysfunction. 2. Women who are planning pregnancy, pregnant, or breastfeeding. 3. Inability to remain supine for 30 minutes. 4. Inability to provide informed consent. 5. Claustrophobia or other psychiatric disorders. 6. Known allergy to the investigational drug or its excipients. 7. Any other condition that the investigator deems unsuitable for participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelial ovarian cancer Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.